Tenx Stock Forecast
TENX Stock Forecast: The Average TENX Stock Forecast for the next 12 months is $5
Latest Stock Price
Tenx Stock Forecast: Fundamental Analysis
In the 3rd quarter of 2022, Tenax reported EPS of $-0.11. Its price-to-equity ratio is -1.22x. for the end of the year 2021, its P/E ratio stood and -0.65x and this inculcates that the stock is burning down its cash on hand. As of 2021, its free cash flow per share has also declined to $-0.53. However, as of 2021, the company’s current ratio stands at 3.64x. The company has 44.7 million shares outstanding and its market capitalization is valued at $6.04 million. To date, the company has no debt and is wholly reliant on equity and warrants.
Tenx Stock Forecast: Latest Video
Tenx Stock Forecast: Latest News
Drugs to be on phase 3 trial – The Company exclusively focuses on Pulmonary Hypertension diseases which are of 2 types. For both types of diseases, the company has been excessively researching and developing 2 drug programs – TNX-201 and TNX-103. And they have finally received permission from FDA to carry out a phase 3 trial.
Tenx Stock Forecast: Q3 Results
- No Revenue has been generated from the time of its inception since the company is still in the Research phase for its drugs.
- It incurred an expense of $1.54million versus $1.52 million in Q2 for research and development.
- It stands a net loss of $2.9 million versus a net loss of $2.8 million in Q2 and its EBITDA for Q3 was $-2.8 million.
- Its cash and cash equivalents have reduced from $7.2 million in Q2 to $3.8 million in Q3.
- By the end of September, Rich Stuart the managing director sold 2 million shares.
Tenx Stock Forecast: Price Prediction for the next 12 months
|The average forecast for the next 12 months||$5|
Tenx Stock Forecast: Why has the stock soared?
Within a span of a day, the stock price has hiked by 45.7%. This company was incorporated in 2008 and is now prevailing at a highly undervalued price of $0.135. Read further to decipher the rise of the stock price –
The pharmaceutical index has shown a slight increase for the past 5 days which could inadvertently have a positive effect on the stock that generates no revenue. The area of specialization for this company is treating PAH (Pulmonary Arterial Hypertension) and Pulmonary Hypertension with HFpEF. There are listed companies that sell medications for PAH disease and they are UTHR, Pfizer, Actelion, and Bayer.
Now, speaking in terms of Tenax’s balance sheet, it has total assets worth $4.7 million and retained assets that are running in a deficit of $286.99. Comprehending the above 2 pieces of information, one can conclude that with its market capitalization valuation, it is cheap enough to be sought out for a buy-out. Especially when one considers the fact that both drug programs are heading for phase 3 trial.
Note: Crowdwisdom360 collates Predictions and data from all over the net and has no in-house view on the likely trends in the Stocks or Crypto Coins. Please consult a registered investment advisor to guide you on your financial decisions.